ASBMR Three Year Pre-Meeting Symposia

ASBMR 三年会前研讨会

• 批准号: 10468525
• 负责人: Teresita M. Bellido
• 金额: $ 4.3万
• 依托单位: AMERICAN SOCIETY FOR BONE & MINERAL RES
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-06-01 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10468525
• 关键词: Address; Affect; American; Area; Award; Basic Science; Biological; Biology; Bone Diseases; Cells; Clinic; Clinical; Clinical Research; Clinical Trials; Defect; Development; Diabetes Mellitus; Disease; Endocrine; Energy Metabolism; Evolution; Functional disorder; Funding; Genes; Genetic; Goals; Grant; Health; Hormones; Hypoxia; Imaging technology; International; Knowledge; Laboratories; Malignant Neoplasms; Mediating; Medical Societies; Metabolic Diseases; Metabolism; Minerals; Mitochondria; Morbidity - disease rate; Musculoskeletal; Musculoskeletal Diseases; Organ; Osteocytes; Osteoporosis; Pathogenesis; Patient Care; Patients; Professional Organizations; Rare Diseases; Recording of previous events; Research; Research Personnel; Role; Science; Scientific Societies; Scientist; Series; Signal Transduction; Skeletal Development; Skeleton; Societies; State-of-the-Art Reviews; Syndrome; Therapeutic; Therapeutic Uses; Translating; Translational Research; United States National Institutes of Health; Update; Woman; base; bone; bone health; direct application; disability; drug discovery; drug repurposing; effective therapy; genetic technology; improved; innovation; interest; meetings; men; mortality; novel strategies; novel therapeutics; posters; pre-clinical; preclinical development; prevent; programs; response; skeletal; skeletal disorder; success; symposium; therapeutic target

The American Society for Bone and Mineral Research (ASBMR), the largest professional, scientific and medical society established to bring together clinical and laboratory-based scientists who are involved in the study of bone, mineral and musculoskeletal science, has had a successful history of conducting annual topical meetings funded by single year NIH R13 grants since 2002. More recently, ASBMR received two, three-year R13 grants to cover pre-meeting symposia programs for 2016-2018 and 2019-2021. The current application seeks funding for a three-year R13 grant to advance the field of musculoskeletal diseases by focusing on three specific areas of scientific research in 2022, 2023 and 2024: 1) “Rare Diseases: From Molecules and Mechanisms to Therapeutics”; 2) “Osteocytes in Bone Health and Disease and as Therapeutic Target Cells”; 3) “Energy Metabolism in Skeletal Development and Disease”. These three symposia cover highly relevant areas of musculoskeletal research that has recently undergone rapid evolution in scientific knowledge and collectively contribute to major clinical morbidity disability and mortality. The overall objective of this R13 is to stimulate further advances that will result in improved patient care for musculoskeletal diseases by bringing together the best researchers for each of the three symposia. The symposia will review the state of the art in each topic area, exchanging ideas with attendees, and stimulating the interaction between young and established researchers. Symposia attendees will be encouraged to attend the subsequent ASBMR Annual Meetings for additional opportunities to interact with musculoskeletal researchers. Programs for all three symposia were developed by an organizing committee, and all speakers for the first two symposia have confirmed their participation. Presenters include established and young investigators, women and men, and, since about half of ASBMR membership is from outside the US, a number of key international speakers have also been invited. Poster sessions, young investigator award presentations, and at the end of each meeting a “dine-around” evening are planned to promote direct interaction between young investigators and more senior speakers. In 2022, the symposium will gather international experts in rare bone diseases to discuss the latest advances on underlying mechanisms and therapies, provide guidance to clinicians on how to recognize them, and lessons learnt from rare diseases that have direct application to more common bone diseases such as osteoporosis. In 2023, the symposium will review the advances in basic, translational and clinical research on the role of osteocytes in the biology and pathophysiology of bone, and how to target osteocytes with therapeutic goals. The osteocyte role in mechanobiology, hormone actions, cancer in bone and osteocyte endocrine actions will be discussed. The 2024 symposium will discuss the recent advances on the role of energy metabolism in skeletal development and disease; including the role of hypoxia and mitochondria-mediated mechanisms, and its involvement in the response of bone to anabolic therapies and metabolic diseases such as diabetes.

美国骨与矿物研究学会（ASBMR），最大的专业，科学和医学 建立的社会是将参与研究的临床和实验室科学家汇集在一起 骨骼，矿物质和肌肉骨骼科学已经成功地进行了年度主题会议的历史 自2002年以来由单年NIH R13赠款资助。最近，ASBMR获得了两份，三年的R13赠款 涵盖2016 - 2018年和2019 - 2021年会议前的研讨会计划。当前申请寻求资金 为期三年的R13赠款，通过专注于三个特定领域来推动肌肉骨骼疾病的领域 2022年，2023年和2024年的科学研究：1）“罕见疾病：从分子和机制到 治疗学”； 2）“骨骼健康和疾病中的骨细胞以及作为治疗靶细胞”； 3）“能量 骨骼发育和疾病中的代谢”。这三个研讨会涵盖了高度相关的领域 最近在科学知识中快速发展的肌肉骨骼研究 有助于主要的临床发病率和死亡率。 R13的总体目标是刺激 进一步的进步将通过将肌肉骨骼疾病的患者护理改善，通过将 三个研讨会中的每一个最佳研究人员。研讨会将在每个主题领域中审查最新技术， 与与会者交流想法，并刺激年轻研究人员和成熟研究人员之间的相互作用。 座谈会的参与者将被鼓励参加随后的ASBMR年度会议以供其他 与肌肉骨骼研究人员互动的机会。所有三个研讨会的程序均由 一个组织委员会以及前两个研讨会的所有发言人都证实了他们的参与。 演示者包括成熟的和年轻的调查员，男女，以及自ASBMR大约一半以来 会员资格来自美国以外，也邀请了许多国际发言人。海报 会议，年轻调查员奖演讲，以及每次会议结束时，即使是“用餐” 计划促进年轻调查员与更多高级演讲者之间的直接互动。在2022年 研讨会将收集稀有骨骼疾病的国际专家，讨论有关基础的最新进展 机制和疗法，向临床医生提供有关如何识别它们的指导，并从中学到了教训 罕见的疾病直接应用于更常见的骨骼疾病，例如骨质疏松症。在2023年， 研讨会将回顾骨细胞在骨细胞中的作用的基础，翻译和临床研究的进步 骨骼的生物学和病理生理学，以及如何靶向具有治疗目标的骨细胞。骨细胞在 将讨论机械生物学，激素作用，骨骼和骨细胞内分泌作用中的癌症。 2024年 研讨会将讨论能量代谢在骨骼发育中的作用的最新进展和 疾病;包括缺氧和线粒体介导的机制的作用，及其参与 骨骼对合成代谢疗法和代谢疾病（例如糖尿病）的反应。